This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.
IVD Market Sustains Momentum: 3 Stocks in Focus
by Trina Mukherjee
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
by Zacks Equity Research
The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.
Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
by Zacks Equity Research
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
by Zacks Equity Research
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
by Zacks Equity Research
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
J&J Submits BLA for Subcutaneous Formulation of Darzalex
by Zacks Equity Research
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
by Zacks Equity Research
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
Amgen & Novartis' Alzheimer Studies End in Another Failure
by Zacks Equity Research
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
Aimmune Down on Negative ICER Review on Allergy Candidate
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
by Kinjel Shah
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?
by Zacks Equity Research
Bristol-Myers (BMY) declines on uncertainty and delay of the Celgene merger.
Novo Nordisk Reports Encouraging Data From Hemophilia Studies
by Zacks Equity Research
Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.
Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
by Zacks Equity Research
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs
by Kinjel Shah
Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.
Will MedTech Ease Investors' Concern & Outperform? 4 Picks
by Urmimala Biswas
Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.
Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
by Zacks Equity Research
Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Roche's Flu Medicine Xofluza Meets Goal in Study on Kids
by Zacks Equity Research
Roche's (RHHBY) new flu medicine, Xofluza is well tolerated in a study in children aged between one to 12 years. It is also comparable to Roche's older flu medicine, Tamiflu,
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
by Zacks Equity Research
Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.
Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer
by Zacks Equity Research
Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer.
Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.